This phase is a double-blind, placebo controlled efficacy and safety trial in adults following hip or knee replacement surgery.
The third study will test the new product on 400 patients, randomized 3:1, and will be conducted at 45 academic and community hospitals in the country.
The ARX-01 system is designed to address the limitations of current PCA with morphine by offering a high therapeutic index opioid with low instance of drug-related side effects.
More Articles on Anesthesia:
Anesthesiology: Blood Clotting Algorithms Can Reduce Bleeding, Hospital Costs
How Happy Are Anesthesiologists?
Dr. Timothy Starck Elected New Vice President of Illinois Society of Anesthesiologists
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
